StockpollyBeta
Get App
Popularity #1,648
RCKT · NASDAQ · Biotechnology

Rocket Pharmaceuticals (RCKT)

Develops gene therapies for rare immune and cardiovascular disorders.

$3.43
After-hours close+0.08 (+2.24%)
At close$3.36(+2.60%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue002200000020
Gross profit00−2−2000000−20
656365716963647152444647
Research & development474244454237364334293129
192221272725282518151717
Selling & marketing00−1−100000000
General & administrative192222272725282518151717
Other expenses0000000300−20
Operating income−65−63−67−74−69−63−64−71−52−44−49−47
44543232211179
Interest income446533432610
Interest expense000000000300
Other non-operating income−4−4−6−5−3−3−4−3−2−5−1−179
Income before tax−62−60−62−70−67−60−61−69−50−43−48132
Income tax expense000000000009
Net income from continuing operations−62−60−62−70−67−60−61−69−50−43−48123
Net income−62−60−62−70−67−60−61−69−50−43−48123
EPS, basic−$0.75−$0.64−$0.66−$0.74−$0.71−$0.62−$0.56−$0.62−$0.45−$0.38−$0.42$1.09
EPS, diluted−$0.75−$0.64−$0.66−$0.74−$0.71−$0.62−$0.56−$0.62−$0.45−$0.38−$0.42$1.08
Weighted average shares, basic839394949498110111112111112113
Weighted average shares, diluted839394949498110111112111112115
EBITDA−60−57−59−67−64−57−58−66−47−37−45137
Depreciation & amortization222222333224
EBIT−61−59−62−69−66−60−61−68−50−39−47132